[1-[(1R,2R)-1-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2,3-dihydroxypropoxy]-3-methylpentan-3-yl]oxy-(3-hydroxypentan-3-yl)phosphinic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: [1-[(1R,2R)-1-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2,3-dihydroxypropoxy]-3-methylpentan-3-yl]oxy-(3-hydroxypentan-3-yl)phosphinic acid
• 化学式: C₂₀H₃₅N₄O₇P
• 分子量: 474.5
• InChiKey: SIBCSCMVSQFCOH-AOQMIGQVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  32
• 可旋转键数：
  13
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  173
• 氢给体数：
  5
• 氢受体数：
  10

文献信息

• US20140275229A1
  申请人：——

  公开号：US20140275229A1

  公开（公告）日：2014-09-18
• METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT
  申请人：Moderna Therapeutics, Inc.

  公开号：US20160205924A1

  公开（公告）日：2016-07-21

  The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules for their use in improving organ viability and/or longevity.
• MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF
  申请人：Moderna Therapeutics, Inc.

  公开号：US20160256573A1

  公开（公告）日：2016-09-08

  The invention provides compositions and methods for effecting wound healing in a mammal, where the compositions include therapeutic mRNA which incorporate modified nucleosides and nucleotides.